Tibulizumab (ZB-106)
Systemic Sclerosis (SSc)
Key Facts
About Zura Bio
Zura Bio's mission is to dramatically improve the lives of patients with severe autoimmune and inflammatory conditions by developing novel medicines based on dual-pathway antagonism. Since its 2022 founding, the company has rapidly built a promising clinical pipeline through the strategic in-licensing of three assets from Eli Lilly and Pfizer, culminating in a public listing via SPAC merger in 2023. With a seasoned leadership team and over $400 million raised to date, Zura is advancing its lead candidate, tibulizumab, through Phase 2 proof-of-concept studies, positioning itself as a capital-efficient disruptor in the autoimmune therapeutics space.
View full company profileAbout Zura Bio
Zura Bio's mission is to dramatically improve the lives of patients with severe autoimmune and inflammatory conditions by developing novel medicines based on dual-pathway antagonism. Since its 2022 founding, the company has rapidly built a promising clinical pipeline through the strategic in-licensing of three assets from Eli Lilly and Pfizer, culminating in a public listing via SPAC merger in 2023. With a seasoned leadership team and over $400 million raised to date, Zura is advancing its lead candidate, tibulizumab, through Phase 2 proof-of-concept studies, positioning itself as a capital-efficient disruptor in the autoimmune therapeutics space.
View full company profileTherapeutic Areas
Other Systemic Sclerosis (SSc) Drugs
| Drug | Company | Phase |
|---|---|---|
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |